Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fisetin to Improve Physical Function in Breast Cancer Survivors
NCT05595499Phase 2Recruiting
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Mar 2023
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in breast cancer comparing Arm A (fisetin) with Arm B (placebo) (2 arms). Primary endpoint: 6-minute walk distance at day 60. Started Mar 2023; status: recruiting.
02
Drugs
fisetin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05595499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05595499.